Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the influence of prostate-specific antigen (PSA) kinetics following maximal androgen blockade (MAB) on disease progression and cancer-specific survival in patients with metastatic, hormone-sensitive prostate cancer.
Materials and Methods: One hundred thirty-one patients with metastatic, hormone-sensitive prostate cancer treated with MAB at our institution were included in this study. Patients’ characteristics, PSA at MAB initiation, PSA nadir, time to PSA nadir (TTN), and PSA decline were analyzed by using univariate and multivariate analysis.
Results: At a median follow-up of 30 months, 97 patients (74.0%) showed disease progression and 65 patients (49.6%) died. Fifty-nine patients (45.0%) died from prostate cancer. In the univariate analysis, PSA at MAB initiation, PSA nadir, TTN, and PSA decline were significant predictors of progression-free survival. Also, PSA nadir, TTN, and PSA decline were significant predictors of cancer-specific survival. In the multivariate analysis, higher PSA nadir (≥0.2 ng/ml) and shorter TTN (＜8 months) were independent predictors of shorter progression-free and cancer-specific survival. In the combined analysis of PSA nadir and TTN, patients with higher PSA nadir and shorter TTN had the worst progression-free survival (hazard ratio [HR], 14.098; p＜0.001) and cancer-specific survival (HR, 14.050; p＜0.001) compared with those with lower PSA nadir and longer TTN.
Conclusions: Our results suggest that higher PSA nadir level and shorter TTN following MAB are associated with higher risk of disease progression and poorer survival in patients with metastatic, hormone-sensitive prostate cancer. Furthermore, these two variables have a synergistic effect on the outcome.

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the influence of prostate-specific antigen (PSA) kinetics following maximal androgen blockade (MAB) on disease progression and cancer-specific survival in patients with metastatic, hormone-sensitive prostate cancer.
Materials and Methods: One hundred thirty-one patients with metastatic, hormone-sensitive prostate cancer treated with MAB at our institution were included in this study. Patients’ characteristics, PSA at MAB initiation, PSA nadir, time to PSA nadir (TTN), and PSA decline were analyzed by using univariate and multivariate analysis.
Results: At a median follow-up of 30 months, 97 patients (74.0%) showed disease progression and 65 patients (49.6%) died. Fifty-nine patients (45.0%) died from prostate cancer. In the univariate analysis, PSA at MAB initiation, PSA nadir, TTN, and PSA decline were significant predictors of progression-free survival. Also, PSA nadir, TTN, and PSA decline were significant predictors of cancer-specific survival. In the multivariate analysis, higher PSA nadir (≥0.2 ng/ml) and shorter TTN (＜8 months) were independent predictors of shorter progression-free and cancer-specific survival. In the combined analysis of PSA nadir and TTN, patients with higher PSA nadir and shorter TTN had the worst progression-free survival (hazard ratio [HR], 14.098; p＜0.001) and cancer-specific survival (HR, 14.050; p＜0.001) compared with those with lower PSA nadir and longer TTN.
Conclusions: Our results suggest that higher PSA nadir level and shorter TTN following MAB are associated with higher risk of disease progression and poorer survival in patients with metastatic, hormone-sensitive prostate cancer. Furthermore, these two variables have a synergistic effect on the outcome.

참고문헌 (Reference)

1 김세중, "특집/전립샘암의 발생빈도, 역학 및 진행 양상" 대한의사협회 53 (53): 92-97, 2010

2 박범진, "전이성 전립선암의 호르몬 치료 2개월 후 전립선특이항원 치의 예후적 의의" 대한비뇨기과학회 44 (44): 855-860, 2003

3 박승철, "전립선암 환자에서 병용호르몬차단요법 후 호르몬비의존성전립선암으로 진행을 예측할 수 있는 인자" 대한비뇨기과학회 48 (48): 408-415, 2007

4 Mulders PF, "Value of biochemical markers in the management of disseminated prostatic cancer" 21 : 2-5, 1992

5 Morote J, "Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer" 20 : 209-216, 2005

6 Choueiri TK, "Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy" 115 : 981-987, 2009

7 Miller JI, "The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer" 147 (147): 956-961, 1992

8 Huang SP, "Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy" 15 : 34-41, 2012

9 Petros JA, "Serum PSA after antiandrogen therapy" 20 : 749-756, 1993

10 Furuya Y, "Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer" 60 : 28-32, 1998

11 Cooper EH, "Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer" 66 (66): 1025-1028, 1990

12 Ercole CJ, "Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer" 138 : 1181-1184, 1987

13 Stewart AJ, "Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure" 23 : 6556-6560, 2005

14 Stamey TA, "Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients" 141 : 1088-1090, 1989

15 Park YH, "Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer" 181 : 2520-2524, 2009

16 Kwak C, "Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer" ELSEVIER SCIENCE INC 168 : 995-1000, 2002

17 Arai Y, "Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer" 144 : 1415-1419, 1990

18 Zhou P, "Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy" 23 : 6992-6998, 2005

19 King CR, "Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy" 70 : 1472-1477, 2008

20 Hori S, "Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer" 137 : 235-241, 2011

21 Morote J, "Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer" 108 : 877-881, 2004

22 Benaim EA, "Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer" 59 : 73-78, 2002

23 Sasaki T, "Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis" 14 : 248-252, 2011

24 May M, "Is it possible to provide a prognosis after radical prostatectomy for prostate cancer by means of a PSA regression model?" 20 : 112-118, 2005

25 Huang SP, "Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy" 71 : 1189-1197, 2011

26 Ross RW, "Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect" 112 : 1247-1253, 2008

27 Lee SY, "Clinical response of combined androgen blockade in metastatic prostate cancers" 41 : 361-366, 2000

28 D'Amico AV, "Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer" 280 : 969-974, 1998

29 Hussain M, "Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)" 24 : 3984-3990, 2006